Comparative Effectiveness Study of Home-Based Interventions to Prevent CA-MRSA Infection Recurrence

Jonathan N. Tobin 1,2,* , Suzanne Hower 1 , Brianna M. D’Orazio 1 , María Pardos de la Gándara 2,3,†, Teresa H. Evering 2,4, Chamanara Khalida 1 , Jessica Ramachandran 1,5, Leidy Johana González 1,5, Rhonda G. Kost 2, Kimberly S. Vasquez 2, Herminia de Lencastre 6,7 , Alexander Tomasz 6, Barry S. Coller 2 and Roger Vaughan 2

Abstract: Recurrent skin and soft tissue infections (SSTI) caused by Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) or Methicillin-Sensitive Staphylococcus aureus (CA-MSSA) present treatment challenges. This community-based trial examined the effectiveness of an evidence-based intervention (CDC Guidelines, topical decolonization, surface decontamination) to reduce SSTI recurrence, mitigate household contamination/transmission, and improve patient-reported outcomes. Participants (n = 186) were individuals with confirmed MRSA(+)/MSSA(+) SSTIs and their household members. During home visits; Community Health Workers/Promotoras provided hygiene instructions; a five-day supply of nasal mupirocin; chlorhexidine for body cleansing; and household disinfecting wipes (Experimental; EXP) or Usual Care Control (UC) pamphlets. Primary outcome was six-month SSTI recurrence from electronic health records (EHR). Home visits (months 0; 3) and telephone assessments (months 0; 1; 6) collected self-report data. Index patients and participating household members provided surveillance culture swabs. Secondary outcomes included household surface contamination; household member colonization and transmission; quality of life; and satisfaction with care. There were no significant differences in SSTI recurrence between EXP and UC in the intent-to-treat cohort (n = 186) or the enrolled cohort (n = 119). EXP participants showed reduced but non-significant colonization rates. EXP and UC did not differ in household member transmission, contaminated surfaces, or patient-reported outcomes. This intervention did not reduce clinician-reported MRSA/MSSA SSTI recurrence. Taken together with other recent studies that employed more intensive decolonization protocols, it is possible that a promotora-delivered intervention instructing treatment for a longer or repetitive duration may be effective and should be examined by future studies.

Keywords: methicillin-resistant Staphylococcus aureus (MRSA); antibiotic-resistance; skin and soft tissue infection (SSTI); community-based participatory research (CBPR); practice-based research network (PBRN); randomized clinical trial (RCT)
1. Introduction

Methicillin-Resistant *Staphylococcus aureus* (MRSA) causes multi-drug resistant infections that pose serious clinical and public health challenges. Skin and soft tissue infections (SSTIs) [1,2] caused by MRSA carry significant morbidity and mortality, and impact patients, families, caregivers, and health-care institutions [3,4]. While studies comparing protocols for reducing healthcare-associated MRSA (HA-MRSA) infections [5] exist, those adapted for community-associated MRSA (CA-MRSA) SSTIs have provided mixed results [6–11]. CA-MRSA SSTIs commonly affect healthy, young individuals without exposure to healthcare risk factors or contacts [12]. (For a list of abbreviations used in this paper see Supplemental Materials: Table S1.)

Most CA-MRSA SSTIs are treated successfully in ambulatory care. However, treatment failure may result in risk of exposure and transmission to household and community members [9,13,14]. Even when primary treatment is successful, recurrent infections are common, ranging from 16% [13,15,16] to 43% [8,17]. Little research has examined the feasibility and effectiveness of implementing evidence-based interventions in primary care settings [18]. This trial tested two community-based interventions: (1) Usual Care (UC): CDC-Guidelines directed care [incision and drainage (I&D) and antibiogram-selected oral antibiotics] versus (2) Experimental (EXP): UC combined with universal household decolonization and environmental decontamination interventions based on the REDUCE MRSA Trial [5,19,20], provided in the home by Community Health Workers (CHW)/Promotoras. We evaluated the comparative effectiveness on SSTI recurrence rates (primary outcome) and household contamination, household member colonization and transmission, and patient-centered measures (pain, depression, quality of life, and care satisfaction; secondary outcomes) using a two-arm 1:1 randomized controlled trial (RCT). We hypothesized that participants assigned to EXP would experience fewer SSTI recurrences compared to UC.

2. Results

2.1. Baseline Comparisons: Experimental versus Usual Care

A total of 602 patients were assessed for eligibility: (Figure 1) 115 from three Federally Qualified Health Centers (FQHCs) and 487 from three Emergency Departments (EDs), of whom 421 (86.4%) provided informed consent, and 186 (44.2%) tested positive for MRSA or MSSA, and were invited to complete the baseline home visit (i.e., “intent-to-treat cohort”). Of 186 eligible consented participants, 120 (65%), completed baseline home visits. Patients who did (n = 120) and did not (n = 66) complete the baseline home visit were similar (Table S2), with equal proportions undergoing I&D (60.7%). Both groups exhibited similar dermatologic symptoms, with no differences in lesion location, size, type, purulence, or signs/symptoms of SSTIs (Table S2). We also compared those who completed the allocated intervention and had 6-month follow-up data (n = 92) to those who received the allocated intervention but did not complete the 6-month follow-up survey (n = 28, Table S3). Rates of I&D, MRSA/MSSA, and recruitment source (FQHC vs. ED) were similar.

No statistically significant differences were detected between EXP and UC in baseline demographics, comorbidity, baseline occupational or environmental or social exposures (Table 1 or in the proportion of household members who participated in the study About half (52.5%) spoke English as their primary language and 36.4% spoke Spanish as their primary language. Microbiological and dermatologic characteristics, and health care utilization were similar (Table S4), but MRSA+ wounds were more common among patients randomized to EXP (66.1%) as compared to UC (32.1%, \( p = 0.0004 \)).
Figure 1. CONSORT Diagram. * “Intent-to-treat” (ITT) cohort (n = 186) ** “Analysis” cohort (n = 119). An additional n = 66 participants were eligible for participation based on having either MRSA+/MSSA+ wound culture and provided informed consent; however, these participants did not complete the baseline home visit, and therefore never received the intervention. Since these participants had consented to be followed, their six-month chart review data were extracted and are provided as an additional “observation-only control group” (n = 63 of these participants were analyzed, for a 95.5% response rate). Upon subsequent chart review, one patient was determined subsequently to have met criteria for HA-MRSA and considered ineligible and these data were removed from the analysis, leaving n = 119 (“analysis cohort”). Data collection spanned from 11/01/2015 to 11/25/2017.
Table 1. Comparison of Study Participants at Baseline for (a) demographics, (b) clinical comorbidity and health care utilization, and (c) occupational and social exposures.

(a) Demographic Characteristics by Treatment Group at Baseline

|                          | Total (n = 119) | Experimental (n = 63) | Usual Care (n = 56) |
|--------------------------|----------------|-----------------------|---------------------|
| **AGE, n (%)**           |                |                       |                     |
| 7–18 years               | 12 (10.1)      | 5 (7.9)               | 7 (12.5)            |
| 19–64 years              | 103 (86.6)     | 55 (87.3)             | 48 (85.7)           |
| over 65                  | 4 (3.4)        | 3 (4.8)               | 1 (1.8)             |
| Mean (SD)                | 38.1 (14.9)    | 39.5 (15.4)           | 36.5 (14.4)         |
| **GENDER, n (%)**        |                |                       |                     |
| Female                   | 47 (39.5)      | 22 (34.9)             | 25 (44.6)           |
| Male                     | 72 (60.5)      | 41 (65.1)             | 31 (55.4)           |
| **ETHNICITY, n (%)**     |                |                       |                     |
| Hispanic or Latino       | 72 (64.9)      | 37 (62.7)             | 35 (67.3)           |
| Not Hispanic or Latino   | 36 (32.4)      | 21 (35.6)             | 15 (28.9)           |
| Prefer not to answer     | 3 (2.7)        | 1 (1.7)               | 2 (3.9)             |
| **RACE, n (%)**          |                |                       |                     |
| American Indian or Alaska Native | 1 (1.0)       | 0 (0)                 | 1 (1.8)             |
| Asian                    | 0 (0)          | 0 (0)                 | 0 (0)               |
| Black or African American| 27 (22.7)      | 14 (22.2)             | 13 (23.3)           |
| White                    | 22 (18.5)      | 13 (20.6)             | 9 (16.1)            |
| More than one race       | 21 (17.6)      | 11 (17.5)             | 10 (17.9)           |
| Prefer not to answer     | 48 (40.3)      | 25 (39.7)             | 23 (41.1)           |
| **BIRTHPLACE, n (%)**    |                |                       |                     |
| One of the 50 U.S. States| 70 (58.5)      | 40 (63.5)             | 54 (53.6)           |
| Puerto Rico              | 7 (5.9)        | 5 (7.9)               | 2 (3.6)             |
| “Other” Country          | 42 (35.3)      | 18 (28.6)             | 24 (42.9)           |
| **Birthplace, if not USA, per self-report, n (%)** | | | |
| Africa (Ivory Coast, Senegal, Other Unspecified) | 3 (7.1) | 2 (11.1) | 1 (4.2) |
| South America (Colombia, Ecuador) | 5 (11.9) | 4 (22.2) | 2 (8.3) |
| North/Central America (Dominican Republic, Guatemala, Honduras, Mexico, Panama) | 29 (69.0) | 12 (66.7) | 17 (70.8) |
| Europe (Russia, Ukraine) | 2 (4.8)        | 0 (0)                 | 2 (8.3)             |
| Asia (Uzbekistan, Yemen) | 3 (7.1)        | 1 (5.6)               | 2 (8.3)             |
| **Length of time in the USA (if non-USA born), n (%)** | | | |
| Less than 10 years       | 96 (80.7)      | 52 (82.5)             | 44 (78.6)           |
| 10 years and over        | 23 (19.3)      | 11 (17.5)             | 12 (21.4)           |
| Years in US, Mean (SD)   | 17.2 (13.7)    | 18 (14.4)             | 16.5 (13.5)         |
| **LANGUAGE SPOKEN AT HOME, n (%)** | | | |
| English                  | 62 (52.5)      | 32 (51.6)             | 30 (53.6)           |
| Spanish                  | 43 (36.4)      | 24 (38.7)             | 7 (12.5)            |
| Other (Portuguese, Ghanaian) | 13 (11.0) | 6 (9.7) | 19 (33.9) |
### Table 1. Cont.

#### (a) Demographic Characteristics by Treatment Group at Baseline

|                              | Total (n = 119) | Experimental (n = 63) | Usual Care (n = 56) |
|------------------------------|-----------------|-----------------------|---------------------|
| **MARITAL STATUS, n (%)**    |                 |                       |                     |
| Married/Living with partner  | 44 (37.3)       | 22 (34.9)             | 22 (40.0)           |
| Widowed                      | 5 (4.2)         | 4 (6.4)               | 1 (1.8)             |
| Divorced                     | 6 (5.1)         | 3 (4.8)               | 3 (5.5)             |
| Separated                    | 7 (5.9)         | 4 (6.4)               | 3 (5.5)             |
| Never Married                | 56 (47.5)       | 30 (47.6)             | 26 (47.3)           |
| Not reported                 | 1               | 0                     | 1                   |
| **HIGHEST DEGREE OR LEVEL OF SCHOOL COMPLETED, n (%)** | | | |
| Below high school            | 46 (39.0)       | 24 (38.7)             | 22 (39.3)           |
| High school or over          | 72 (61.0)       | 38 (61.3)             | 34 (60.7)           |
| Not reported                 | 1               | 1                     | 0                   |
| **COMBINED FAMILY INCOME, n (%)** | | | |
| Less than $10,000            | 33 (27.7)       | 18 (28.6)             | 15 (26.8)           |
| $10,000 or greater           | 57 (47.9)       | 31 (49.2)             | 26 (46.4)           |
| Not reported                 | 29 (24.4)       | 14 (22.2)             | 15 (26.8)           |
| **TYPE OF INSURANCE, n (%)** | | | |
| Private Insurance            | 10 (8.5)        | 5 (7.9)               | 5 (9.1)             |
| Medicare                     | 11 (9.4)        | 7 (11.1)              | 4 (7.3)             |
| Medicaid                     | 56 (47.5)       | 35 (55.6)             | 21 (38.2)           |
| HMO                          | 1 (0.9)         | 1 (1.6)               | 0 (0)               |
| Military or Veteran          | 1 (0.9)         | 0 (0)                 | 1 (1.8)             |
| None                         | 26 (22.0)       | 11 (17.5)             | 15 (27.3)           |
| Other                        | 13 (11.0)       | 4 (6.4)               | 9 (16.4)            |
| **EMPLOYMENT HISTORY, n (%)**| | | |
| Currently Employed           | 56 (47.5)       | 29 (46.8)             | 27 (48.2)           |
| **EXTENT OF EMPLOYMENT, n (%)** | | | |
| Full time                    | 33 (58.9)       | 17 (58.6)             | 16 (59.3)           |
| Part time                    | 23 (41.1)       | 12 (41.4)             | 11 (40.7)           |

#### (b) Comorbidity and Health Care Utilization by Treatment Group at Baseline

|                                | Total (n = 119) | Experimental (n = 63) | Usual Care (n = 56) |
|--------------------------------|-----------------|-----------------------|---------------------|
| **BODY MASS INDEX (BMI), n (%)** |                 |                       |                     |
| Underweight (<18.5)            | 3 (2.8)         | 1 (1.8)               | 2 (3.9)             |
| Normal weight (18.6–24.9)      | 32 (29.6)       | 16 (28.1)             | 16 (31.4)           |
| Overweight (25–29.9)           | 34 (31.5)       | 17 (29.8)             | 17 (33.3)           |
| Obese (≤30)                    | 39 (36.1)       | 23 (40.4)             | 16 (31.4)           |
| Mean (SD)                      | 28.8 (6.5)      | 29.2 (6.3)            | 28.3 (6.8)          |
| **CO-MORBIDITY, n (%)**        |                 |                       |                     |
| Abscess/Boil                   | 108 (90.8)      | 57 (90.5)             | 51 (91.1)           |
| Alcohol Abuse                  | 4 (3.4)         | 3 (4.8)               | 1 (1.8)             |
| Arteriosclerotic               | 8 (6.7)         | 3 (4.8)               | 5 (8.9)             |
| Cardiovascular Disease or      | 20 (17.1)       | 12 (19.4)             | 8 (14.6)            |
| Coronary Artery Disease        |                 |                       |                     |
| Asthma                         |                 |                       |                     |
| Table 1. Cont. |
|---------------|
| (a) Demographic Characteristics by Treatment Group at Baseline |
|               | Total (n = 119) | Experimental (n = 63) | Usual Care (n = 56) |
| **MARITAL STATUS, n (%)** |               |                     |                     |
| Chronic Liver Disease       | 3 (2.5)        | 2 (3.2)              | 1 (1.8)             |
| Chronic Renal Insufficiency | 6 (5.0)        | 4 (6.4)              | 2 (3.6)             |
| Chronic Skin Breakdown      | 6 (5.1)        | 3 (4.8)              | 3 (5.4)             |
| Current Smoker              | 33 (28.2)      | 17 (27.4)            | 16 (29.1)           |
| Cerebrovascular Accident (CVA)/Stroke (Not Transient Ischemic Attack (TIA)) | 6 (5.1) | 3 (4.8) | 3 (5.5) |
| Cystic Fibrosis             | 0 (0)          | 0 (0)                | 0 (0)               |
| Decubitus/Pressure Ulcer    | 2 (1.7)        | 2 (3.2)              | 0 (0)               |
| Dementia                    | 1 (0.9)        | 0 (0)                | 1 (1.8)             |
| Diabetes                    | 29 (24.6)      | 16 (25.8)            | 13 (23.2)           |
| Emphysema/Chronic obstructive Pulmonary Disease (COPD) | 3 (2.7) | 3 (5.1) | 0 (0) |
| Heart Failure               | 4 (3.4)        | 4 (6.4)              | 0 (0)               |
| Hematologic Malignancy      | 1 (0.8)        | 1 (1.6)              | 0 (0)               |
| Hemiplegia/Paraplegia       | 1 (0.8)        | 0 (0)                | 1 (1.8)             |
| HIV or AIDS                 | 4 (3.4)        | 1 (1.6)              | 3 (5.4)             |
| Immunosuppressive Therapy   | 3 (2.5)        | 2 (3.2)              | 1 (1.8)             |
| Intravenous Drug Use        | 5 (4.2)        | 4 (6.4)              | 1 (1.8)             |
| Metastatic Solid Tumor      | 2 (1.7)        | 2 (3.2)              | 0 (0)               |
| Obesity                     | 16 (13.7)      | 8 (13.1)             | 8 (14.3)            |
| Other Drug Use              | 9 (7.6)        | 4 (6.5)              | 5 (8.9)             |
| Peptic Ulcer Disease        | 4 (3.4)        | 3 (4.8)              | 1 (1.8)             |
| Peripheral Vascular Disease | 1 (0.8)        | 1 (1.6)              | 0 (0)               |
| Rheumatoid Arthritis        | 1 (0.9)        | 0 (0)                | 1 (1.9)             |
| Sickle Cell Anemia          | 2 (1.7)        | 2 (3.2)              | 0 (0)               |
| Systemic Lupus              | 2 (1.7)        | 1 (1.6)              | 1 (1.8)             |
| **HEALTHCARE UTILIZATION: Six Months Prior to Baseline, n (%)** |               |                     |                     |
| Hospitalized                | 37 (31.1)      | 24 (38.1)            | 13 (23.2)           |
| Nights hospitalized, Mean (SD) | 3.0 (8.3)     | 3.1 (6.8)            | 2.9 (9.8)           |
| Visited ED/Urgent care facility | 106 (89.1)  | 54 (85.7)            | 52 (92.9)           |
| Visits to ED/Urgent care facility, Mean (SD) | 1.9 (2.2) | 2.0 (2.6) | 1.9 (1.5) |
| **Doctor Visits, n (%)**    |               |                     |                     |
| ≤3                          | 88 (74.6)      | 47 (75.8)            | 41 (73.2)           |
| 4 to 8                      | 18 (15.3)      | 8 (12.9)             | 10 (17.9)           |
| ≥9                          | 12 (10.2)      | 7 (11.3)             | 5 (8.9)             |
| Mean (SD)                   | 3.1 (5.3)      | 3.1 (5.6)            | 3.1 (5.1)           |
| **MEDICAL HISTORY, n (%)**  |               |                     |                     |
| Prior Treatment for Same Lesion | 32 (27.1)   | 14 (22.6)            | 18 (32.1)           |
| Family/Friends with Same Lesion | 15 (12.6)  | 8 (12.7)             | 7 (12.5)            |
| Had Lesion While in School  | 13 (10.9)      | 5 (7.9)              | 8 (14.3)            |
| Had Lesion While Working    | 23 (19.3)      | 12 (19.1)            | 11 (19.6)           |
### Table 1. Cont.

(a) Demographic Characteristics by Treatment Group at Baseline

|                      | Total (n = 119) | Experimental (n = 63) | Usual Care (n = 56) |
|----------------------|-----------------|-----------------------|---------------------|
| **MARITAL STATUS, n (%)** |                 |                       |                     |
| Single               | 37 (31.0)       | 20 (31.7)             | 17 (30.4)           |
| Married              | 82 (69.0)       | 43 (68.3)             | 39 (69.6)           |
| Marital Status Other | 0 (0)           | 0 (0)                 | 0 (0)               |

(c) Occupational and Social Exposures by Treatment Group at Baseline

| OCCUPATIONAL EXPOSURE, n (%) |                      |                       |                     |
|-----------------------------|----------------------|-----------------------|---------------------|
| Healthcare Employee         | 0 (0)                | 0 (0)                 | 0 (0)               |
| Nursing Home Employee       | 1 (0.8)              | 1 (1.6)               | 0 (0)               |
| Daycare Center Employee     | 2 (1.7)              | 1 (1.6)               | 1 (1.8)             |
| Correctional Facility       | 1 (0.8)              | 1 (1.6)               | 0 (0)               |
| Animal Facility Employee    | 1 (0.8)              |                       | 0 (0)               |

| ENVIRONMENTAL EXPOSURES, n (%) |                      |                       |                     |
|-------------------------------|----------------------|-----------------------|---------------------|
| Handwashes per Day:          |                      |                       |                     |
| 0–1 time                      | 0 (0)                | 0 (0)                 | 0 (0)               |
| 2–3 times                     | 11 (9.2)             | 6 (9.5)               | 5 (8.9)             |
| 4–6 times                     | 44 (37.0)            | 23 (36.5)             | 21 (37.5)           |
| 7–10 times                    | 25 (21.0)            | 12 (19.1)             | 13 (23.2)           |
| >10 times                     | 39 (32.8)            | 22 (34.9)             | 17 (30.4)           |
| In Month Prior to Baseline:  |                      |                       |                     |
| Surgery                       | 8 (6.7)              | 6 (9.5)               | 2 (3.6)             |
| Wounds, cuts, abrasions       | 33 (27.7)            | 16 (25.4)             | 17 (30.4)           |
| Spent in hospital            | 39 (32.8)            | 24 (38.1)             | 15 (26.8)           |
| International Travel         | 7 (5.9)              | 4 (6.4)               | 3 (5.4)             |
| Incarceration                | 0 (0)                | 0 (0)                 | 0 (0)               |
| Lived in Dormitory           | 3 (2.5)              | 0 (0)                 | 3 (5.4)             |
| Lived in Military Barracks   | 0 (0)                | 0 (0)                 | 0 (0)               |
| Taken Antibiotics            | 105 (88.2)           | 55 (87.3)             | 50 (89.3)           |
| Spent time at Daycare Center | 6 (5.1)              | 4 (6.5)               | 2 (3.6)             |
| Played Contact Sports        | 17 (14.3)            | 7 (11.1)              | 10 (17.9)           |
| Had Pets in the House        | 40 (33.6)            | 19 (30.2)             | 21 (37.5)           |

| SOCIAL NETWORK, n (%) |                      |                       |                     |
|----------------------|----------------------|-----------------------|---------------------|
| How many people live in your house? |                 |                       |                     |
| Lives alone (one person household) | 7 (5.9)             | 5 (7.9)               | 2 (3.6)             |
| 2–3 people           | 52 (43.7)            | 31 (49.2)             | 21 (37.5)           |
| 4 or over            | 60 (50.4)            | 27 (42.9)             | 33 (58.9)           |
| Sharing Characteristics |                      |                       |                     |
| Shared Bedroom or Sleeping Space | 62 (52.1)           | 31 (49.2)             | 31 (55.4)           |
| Shared Bath Towels   | 12 (10.2)            | 8 (12.7)              | 4 (7.3)             |
| Household Member Risk Factors |                 |                       |                     |
| Household Member with Recent SSTI | 1 (0.8)             | 1 (1.6)               | 0 (0)               |
| Household Member with Recent Surgery | 7 (5.9)             | 4 (6.4)               | 3 (5.4)             |
| Household Member Works in Healthcare | 12 (10.1)           | 7 (11.1)              | 5 (8.9)             |

Note: No significant differences at baseline were observed between experimental and control groups at an alpha (2-tailed) = 0.05 with the exception of: (1) MRSA+ wound cultures, which were more common in the experimental group and MSSA+ wound cultures, which were more common in the usual care group (both ps = 0.0004), (2) USA 300 was more common in the experimental group (52%) as compared to the control group (32%, p = 0.03).
2.2. SSTI Recurrence

We used logistic regression analyses to detect treatment group differences on EHR-documented SSTI recurrence at six-month follow-up (Table 2). We conducted initial main effects analysis using all randomized subjects (n = 186, “intent-to-treat cohort”). Based on the sensitivity analysis, we conducted all further analyses using completed cases (n = 119, “analysis cohort”). The ITT analysis demonstrated no significant differences in infection recurrence between EXP (11.1%) and UC (10.7%; OR = 1.4, 95% CI = 0.51–3.5). Likewise, when examining the analysis cohort, there were no statistically significant differences between EXP and UC on EHR-documented SSTI recurrence: 11.1% of EXP vs. 10.7% of UC had a documented SSTI recurrence (OR = 1.14, 95% CI = 0.35, 3.6; Table 2).

Table 2. SSTI recurrence in Index Patients at six-month follow-up.

| Total b (n = 119) | Experimental (n = 63) | Usual Care (n = 56) | OR (95% CI) | p-Value |
|-------------------|------------------------|---------------------|-------------|---------|
| Prospective, n (%)|                        |                     |             |         |
| EHR-Based (n = 119) | 13 (10.9) c            | 7 (11.1)            | 6 (10.7)    | 1.14 (0.35, 3.6) | 0.82 |
| Self-Report (n = 92) | 15 (15.3)              | 10 (22.2)           | 3 (7.5)     | 3.5 (0.89, 13.8) | 0.07 |
| Combined Measure | 24 (20.3)               | 15 (24.2)           | 9 (16.1)    | 1.7 (0.66, 4.2)  | 0.27 |

Notes: a Prospective recurrence is defined as report of a new SSTI in the 6-month period following the initial (baseline) infection for which the participant was recruited. EHR-based outcomes were assessed at 6-months post-baseline and include the time period 12 months prior and 6 months after the baseline infection. At the baseline telephone assessment (T0), and prospective recurrence was assessed at the 6-month telephone assessment (T4). b Total n differs by data source: EHR-based (n = 119), Self-Report (n = 92). All analyses are unadjusted for covariates. c The observed prospective recurrence rate at 6-month EHR review for the Observation Only Group (n = 66, 10.5%) was not different from either the Experimental (11.1%) or Usual Care (10.7%) or Total (10.7%).

Differences in SSTI recurrence based on self-report (Table 2) showed a trend in the opposite direction: EXP reported a greater recurrence rate at 6 months (22.2%) than UC (7.5%, OR = 3.5, 95% CI = 0.89, 13.8). Given the differences between EHR-documented and self-reported recurrence we examined concordance by treatment group and by baseline wound characterization. 15.4% of participants with a self-reported SSTI recurrence also had a documented clinical SSTI recurrence. Retrospective self-report of pre-study infections found 30.5% of participants reported ≥1 prior SSTI, whereas 90.7% of participants had documented pre-study SSTIs in their EHRs, indicating poor concordance between EHR and self-report.

The ITT analysis resulted in similar trends when restricted to the enrolled analysis cohort. We also added one additional unplanned analysis comparing the EHR-measured 6-month SSTI outcome with an “observation only control group” (n = 66) comprised of eligible individuals with a confirmed MRSA+/MSSA+ wound culture who had initially consented to participate, but did not complete the baseline home visit, so their randomization assignment was never disclosed to these participants or study staff (Table S2). These participants did not receive any intervention or assessment beyond what was extracted from the EHR, and had no further interactions with research staff, although they continued to receive care where they were recruited. The observed prospective SSTI recurrence rate at 6-month EHR review for the “observation only control group” (10.5%) was similar to those of the EXP (11.1%) and UC (10.7%) groups.

2.3. Index Patient Colonization

Index patient colonization (nares, axilla, and groin) was measured at baseline and three months. Similar baseline colonization rates were observed: nares (EXP = 41.3% vs. UC = 32.1%), axilla (EXP = 34.9% vs. UC = 32.1%), groin (EXP = 49.2% vs. UC = 44.6%; Figure 2a). S. aureus was recovered at baseline from at least one site (Figure 2b) in most patients (EXP = 74.6% vs. UC = 66.1%). While most patients were colonized at one site
(EXP = 34.9\% vs. UC = 35.7\%), some were colonized at two (EXP = 28.6\% vs. UC = 17.9\%) or three sites (EXP = 11.1\% vs. UC = 12.5\%).

Figure 2. (a) Proportion of Index Patient \textit{S. aureus} Colonization by Colonization Site at Baseline and Three Month Follow-up Household Visits. (b) Proportion of Index Patient \textit{S. aureus} Colonization by Number of Colonized Sites at Baseline and Three Month Follow-up Household Visits.
Three months post-intervention, there was an overall reduction in colonization, with *S. aureus* less frequently recovered from all body sites. Implementation of the decolonization intervention demonstrated that colonization rates in EXP were non-significantly reduced at three months for nares (OR = 0.41, 95% CI = 0.16–1.04), axilla (OR = 0.77, 95% CI = 0.31–1.91) and groin (OR = 0.53, 95% CI = 0.24–1.20), whereas there were little decreases in UC (Figure 2a). Overall, the increase in participants with no organisms detected at three months was greater in EXP (36.5% point increase) as compared to UC (17.2% point increase; Figure 2b). We did not observe any increase in mupirocin resistance between baseline (3%) and three months (0%; data not shown).

2.4. Patient-Centered Outcomes

No intervention-related behavioral changes were observed, including infection prevention knowledge and hygiene, prevention self-efficacy, decision-making autonomy, mupirocin and chlorhexidine adherence, quality of life (QoL) or patient satisfaction (Table S5).

2.5. Household Surfaces Contamination

At baseline, the most frequently contaminated surfaces included: toilet seat (EXP = 52.4% vs. UC = 53.6%), bedroom floor (EXP = 49.2% vs. UC = 60.7%), and kitchen floor (EXP = 60.3% vs. UC = 58.9%; Figure 3a), and most households had ≥1 contaminated surfaces (EXP = 96.8% vs. UC = 96.4%). Both groups showed similar reductions in environmental contamination (Figure 3b). There were no differences in reductions in proportions of households with ≥1 contaminated surfaces, EXP (96.8% to 60.3%) vs. UC (96.4% to 66.1%). Linear regression examining the average difference in numbers of contaminated surfaces (0–13) showed that there were 0.31 fewer contaminated surfaces at follow-up in EXP versus UC, after adjusting for baseline number of contaminated surfaces ($p = 0.08$; data not shown). Multivariate models with treatment allocation and number of household surfaces did not reveal any associations among these environmental-level factors and SSTI recurrence.
2.6. Household Members Colonization and Reported Infection

Consenting household members were screened for colonization (nares, axilla, groin) at baseline and three months. 64.1% of household members provided surveillance cultures (EXP = 67.5%, UC = 60.2%, p = 0.34; see Figure 4a, b). Among household members, similar reductions in proportions of colonized sites were seen for nares (EXP 27.0% to 17.5% vs. UC 23.2% to 17.9%), axilla (EXP 17.5% to 9.5% vs. UC 14.3% to 10.7%) and groin (EXP 28.6% to 19.1% vs. UC 21.4% to 19.6%; Figure 2a). There was a non-significant reduction in household member colonization for EXP (9.5% to 3.2%) versus UC (8.9% to 5.4%). MSSA+ household members were similar at baseline and three-month follow-up in both EXP and UC, with no observed reductions in percentages of household members colonized by MSSA (Figure 2b).
Figure 4. (a) Proportion of household members colonized with *S. aureus*, by colonization site at baseline and three month follow-up household visits. (b) Household members colonized with MRSA vs. MSSA by treatment group at baseline and three-month follow-up household visits. Note: In addition to the Index Patient information provided above, 64% of household members participated in the study and provided surveillance cultures (EXP = 67.5%, UC = 60.2%, *p* = 0.34) There were no significant differences by treatment group in the number of co-residents in households where the index patient had a MRSA wound (EXP = 2.4 vs. UC = 3.4, *p* = 0.06).
2.7. Subgroup Considerations/Heterogeneity of Treatment Effects (HTE)

We conducted pre-specified subgroup analyses using logistic regression with treatment assignment and with each subgroup coded as dummy variables. Consistent with previous studies [21], foreign-born participants were more likely to have MSSA+ than MRSA+ wound cultures. Other HTE subgroup comparisons (wound culture type (MRSA vs. MSSA), birthplace (USA vs. non-USA), household contamination levels (low vs. high), household members colonization (present vs. absent), pets living in the household (present vs. absent), recruitment site (ED vs. FQHC), and baseline I&D treatment (yes vs. no)) revealed no statistically significant differences for EHR-documented SSTI recurrence (data not shown).

3. Discussion

This study adapted and implemented an effective hospital ICU-based intervention [5] into the community. We examined the comparative effectiveness of usual care: CDC/Guidelines-directed care [19,20] versus an experimental intervention: UC combined with universal decolonization and environmental decontamination [5,19,20]. Results suggest that this was a null trial. There were few observed hypothesized intervention-related differences for clinical, microbiological and patient-centered outcomes.

The primary and secondary outcomes analyses indicated that EXP fared as well as UC. Despite a significant baseline difference in MRSA-positive (more common in EXP) and MSSA-positive (more common in UC) cultures which we had not anticipated and therefore did not stratify during randomization, we saw no evidence that this baseline imbalance affected the analyses.

Interestingly, the overall study rate of SSTI recurrence was substantially lower (10.8%) than in previous studies [22,23], although a recent cohort study reported a comparable 3-month recurrence rate (10.3%) [9]. It is possible that high study rates of I&D plus oral antibiotics contributed to the lower-than-expected SSTI recurrence rate. One recruitment site, a large public hospital ED, predominated, which might explain a lower-than-expected recurrence since treatments used there have been demonstrated effective in preventing treatment failure and SSTI recurrence [9,24]; thus, suggesting a statistical floor effect hindered detection of differences in recurrence. Similarly, the low event rates of household and environmental outcomes reduced the study’s power to detect significant treatment effects. Finally, EXP were more likely to have no detectable S. aureus colonization at three months, but again the difference was not significant.

The environmental persistence of S. aureus and as a colonizer despite active eradication efforts is well-documented and multifactorial [8,25–27] and likely modulated by interactions inside the household and surrounding community [9,15,28,29]. Overall, the percent of households with no environmental contamination increased substantially (from 3.2% to 39.7%). However, 60.3% of households were still contaminated and enhanced antimicrobial measures were not more effective [8] than standard patient education and UC. This reflects the inherent challenges of eradicating this opportunistic pathogen in residential settings. While previous studies have demonstrated higher rates of colonization and contamination are associated with recurrence [17,29,30], there are conflicting reports of whether reduction in bioburden translates into less recurrence [18,31,32]. Previous interventions to reduce S. aureus carriage and SSTI recurrence provide mixed results [6,8,10,11,18,32–34]. Interestingly, Golding et al. showed community education focusing on patient and household hygiene decreased SSTI incidence [35]. The universally distributed Living with MRSA pamphlet [36] likely contributed to total study recurrence reduction, potentially obscuring the intervention impact.

3.1. Study Limitations

This study’s results likely reflect unmeasured and uncontrolled variables, including adherence and effectiveness of bioburden reduction and microbial dynamics in an open system [26]. Additionally, there were significantly more MRSA+ wounds in EXP vs. UC despite randomization. This higher MRSA bioburden may have made decolonization and
decontamination more challenging [29], thereby obfuscating any study treatment-related differences. Since EXP participants were aware of the intervention methods, it is plausible that their sensitization led participants to focus on minor skin symptoms that were ignored by UC, resulting in higher self-reported SSTI recurrence.

In order to minimize the burden of multiple home visits and increase study participation, follow-up sampling took place at three months, rather than immediately following initial decolonization and decontamination. Therefore, the immediate effectiveness of the experimental protocol was not measured. It is possible that organisms detected after three-months were not eradicated at baseline since S. aureus can exhibit long-term survival on surfaces [37]. However, host recolonization and replenishment of the environment over time is also possible.

3.2. Future Directions

Implementing common hospital cleaning protocols [5,38] within a community setting was a formidable challenge and warrants further investigation. Future studies should stratify on infection wound culture type (MRSA(+) vs. MSSA(+) prior to randomization, to ensure balance in treatment assignment, and may wish to power each subgroup sufficiently for SSTI recurrence, as well as measure effects of active antimicrobial measures immediately following completion of the regimen. While nasal decolonization routine herein is standard practice [20], it is possible that a longer and/or more potent decolonization protocol is required to reduce MRSA recurrence [11,23,30,39]. In fact, recent studies implementing a similar yet more intense decolonization intervention decreased MRSA infection recurrence [11,39]. These data, combined with our data, indicate that greater frequency and longer duration of decolonization may be required.

4. Materials and Methods

This RCT included practicing clinicians, patients, clinical and laboratory researchers, NY-based Federally Qualified Health Centers (FQHCs) and community hospital Emergency Departments (EDs). The stakeholder research collaborative expands an earlier partnership, the Community-Acquired MRSA Project (CAMP1) which developed research to address CA-MRSA [21,40–42]. The study was approved by Institutional Review Boards at Clinical Directors Network and Rockefeller University.

4.1. Study Setting

Three NYC FQHCs and three EDs recruited participants presenting with an SSTI with culture-positive MRSA or MSSA.

4.2. Participants

Inclusion/Exclusion Criteria: Participants included were: (1) between 7–70 years, (2) fluent in English or Spanish, (3) planning to receive follow-up care at the FQHC or ED, (4) presenting with SSTI signs/symptoms (5), had laboratory-confirmed baseline wound culture positive for MRSA or MSSA (also a significant cause of SSTIs; (6) willing/able to provide informed consent, and (7) willing to participate in two home visits. Participants were excluded if they were: (1) unwilling to provide informed consent, (2) acutely ill or visibly distressed (for example, crying, wheezing, bleeding, screaming or shaken), and/or (3) unable to participate in home visits or in a discussion about the study.

4.3. Study Protocol

Screening: Patients seeking care for an SSTI were identified via the site’s electronic health record (EHR) or clinical dashboard. CHWs flagged patients for treating clinicians to determine eligibility.

Procedures: Recruitment, informed consent, and baseline clinical assessments were conducted by trained CHW/Promotoras with clinicians and FQHC/ED staff. Following written informed consent, clinicians conducted baseline clinical assessments and collected
wound cultures. Wound and surveillance (nasal, axilla, and groin) cultures were sent to one commercial clinical laboratory (BioReference) for culture, antibiotic susceptibility testing, and speciation. Additional molecular epidemiologic testing was carried out by Rockefeller’s Laboratory of Microbiology and Infectious Diseases [41] Mupirocin susceptibility was tested using E-test strips (bioMérieux, Durham, NC) following CLSI recommendations [43].

All participants received clinician-directed standard-of-care treatment, including I&D and/or oral antibiotics. If I&D was performed, a sample of purulent drainage material was obtained; if I&D was not indicated, the clinicians took a swap of the wound or, if the wound was weeping or draining, obtained purulent material. During the same visit, on-site CHW/Promotoras scheduled the home visit. If a CHW/Promotora or other research staff member was not present, per “warm hand off” procedures [44], clinical staff informed participants that a CHW/Promotora would telephone them.

When culture lab results became available (2-3 days later), medical staff disclosed MRSA/MSSA status. CHW/Promotoras then called each participant to inform them of eligibility. For those with MRSA+ or MSSA+ SSTIs, CHW/Promotoras confirmed the baseline telephone interview appointment and baseline home visit.

4.4. Assessments

Baseline Assessments: Table S6 details the full assessment protocol. A Baseline Telephone Questionnaire including demographics, medical history, comorbidity, social, occupational and environmental exposures, household composition and patient-centered outcomes (Table S6) was administered in English or Spanish.

The Baseline Home Visit Assessment (T1) captured: (1) consenting household members’ demographics, comorbidities, SSTI history, and index patient and household member personal hygiene, (2) household sharing behaviors, (3) collection and retrieval of self-sampled surveillance cultures from the index patient and consenting household member, (4) census of the numbers of rooms, household inhabitants and regular visitors, (5) 13 samples obtained from high touch/high traffic household environmental surfaces (see Figure 4a) using ESwabs™ (Copan Diagnostics, Inc., Murrieta, CA, USA).

CHWs/Promotoras oversaw participants’ and household members’ self-sampling of nares, inguinal folds, and axillae. Prior to randomization, participants received the educational pamphlet, “Living with MRSA”, available in English and Spanish [36].

Follow Up Assessments: Home visits occurred at three-months (T3). Interim telephone assessments at one-month (T2) and six-month follow-up (T4) were conducted (Figure S1). Reviews of EHRs were conducted at T4 to record SSTI recurrence (i.e., one or more discrete clinical SSTI(s) at the same or new site in addition to the baseline infection during the six months following trial enrollment). Patient-reported SSTI recurrence was also recorded. While we had planned to combine SSTI recurrence data from EHR and self-reports, participants’ self-reports had poor concordance with EHR-based clinician reports, so we limited the main analysis to clinician-documented SSTI recurrence. See Figure S1.

Randomization: After baseline questionnaires and household sampling data were collected, and while still at the home, CHWs/Promotoras opened a sealed opaque envelope containing the computer-generated randomization (1:1), overseen by the offsite, blinded study statistician (JCdR). Participants were not stratified during randomization based on recruitment site or pathogen (MRSA or MSSA). If randomized to UC, the CHW/Promotoras explained the timeline for remaining assessments and concluded the visit. No further intervention materials were provided to UC.

Interventions: Modeled on the REDUCE MRSA trial [5], EXP received CDC and Infectious Disease Society of America guidelines-directed usual care [19,38] combined with universal household decolonization and environmental decontamination educational interventions [5] and materials from CHWs/Promotoras. They received detailed verbal, written, and demonstrated instructions of the five-day protocol of twice-daily application of mupirocin ointment to the anterior nares with a clean cotton applicator [45], once-daily
Hibiclens® (chlorhexidine gluconate solution 4% w/v) whole body wash [8,11,19,46], and household decontamination instruction including: (1) proper handwashing technique, (2) laundering bed linens and pillows in warm water every other day, and (3) disinfection of “high touch” environmental surfaces with disposable disinfecting wipes [38,47].

**Retention and Withdrawal:** Participants who withdrew were asked to provide reason(s) for withdrawal (see CONSORT Diagram, Figure 1 above). We attempted to reach all participants until the trial completion date.

4.5. Sample Size Calculations and Power

Sample size estimation was based on SSTI recurrence rate from CAMP1, where 33.3% experienced a recurrence during the six months following their index SSTI [21]; previous studies of HA-MRSA reported reductions between 30% and 55% [48–50]. To achieve 80% power at 5% significance level in a two-sided Chi Square/Fisher’s Exact test for recurrence at 6-month follow-up, estimated sample size requirement was 120 participants (60 per group).

4.6. Analytical and Statistical Approaches

Chi-square tests were applied for comparison of proportions and $t$-tests were used for continuous quantitative variables. All primary main effects outcomes analyses ($n = 186$) were evaluated according to “Intent-to-Treat” (ITT). Subsequent planned analyses included patients who completed the baseline home visit ($n = 119$, “analysis cohort”) and pre-specified subgroups. Logistic regression and generalized linear mixed effect models were used for hypothesis testing. All analyses were conducted with SAS (Version 9.3) or R (Version 3.0). Revised sample size calculations based on a conditional power analysis using the lower observed event rate indicate that the study still had a power > 0.80 to test a 50% reduction given the baseline recurrence rate of 11% (rather than 33%).

4.7. Missing Data/Sensitivity Analyses

Although we observed a small proportion of missing data, data were assumed to be “missing not at random” (MNAR) so we used a sensitivity approach rather than multiple imputation. No meaningful or statistically significant differences were revealed between the original versus sensitivity analysis results.

5. Conclusions

This trial aimed to understand systems-, patient-, pathogen-, and environmental-level factors associated with SSTI recurrence and household transmission (Figure S2). Home visits presented a major challenge. Although the perceived (or actual) intrusiveness of home visits proved difficult to overcome, the “warm hand-off” strategy facilitated a modest improvement in home visit completion rates. The lower-than-expected six-month recurrence rate (10.9% here as compared to our previous observational study of 33.3% [21]) may have limited the power to identify a treatment effect. Multiple well-designed studies conducted in different settings have all converged on similar findings: decolonization and decontamination can be accomplished in the household to varying degrees, but extensive, long-term decontamination may be required to achieve a medically meaningful reduction in disease recurrence. These findings suggest that other mechanisms may also contribute to the disconnect between exposure and outcome, such as intrinsic host factors including immunologic competence, as well as perturbations of the host and environmental microbiomes. These factors warrant further observational and experimental studies.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/antibiotics10091105/s1. Table S1: Abbreviations Used, Table S2: Characteristics of consented participants who completed the baseline home visit (T1) versus patients who did not complete the baseline home visit (T1), Table S3: Demographics of participants who were followed-up vs. not followed-up, Table S4: Microbiologic and dermatologic characteristics of study participants at baseline, Table S5: Patient reported outcome scores at baseline and six months for the total sample, experimental condition, and control condition, Table S6: Measures, data sources and time points, Figure S1: Study procedures and timeline, Figure S2: Conceptual model.
Author Contributions: Conceptualization: J.N.T., T.H.E., R.G.K., H.d.L., A.T.; Methodology: J.N.T., B.M.D., M.P.d.l.G., T.H.E., R.G.K., H.d.L., A.T.; Software: M.P.d.l.G., R.V.; Validation: B.M.D., M.P.d.l.G., R.V.; Formal Analysis: J.N.T., S.H., B.M.D., M.P.d.l.G., R.G.K., H.d.L., A.T., R.V.; Investigation: J.N.T., B.M.D., M.P.d.l.G., C.K., H.d.L., J.R., J.L.G., R.G.K., K.S.V.; Resources: J.N.T., C.K., R.G.K.; Data Curation: B.M.D., M.P.d.l.G., C.K., H.d.L., A.T., R.V.; Writing—Original Draft Preparation: J.N.T., S.H., B.M.D., M.P.d.l.G., T.H.E., C.K., R.G.K., K.S.V., H.d.L., A.T., B.S.C., R.V.; Visualization: J.N.T., S.H., R.V.; Supervision: J.N.T., B.M.D., C.K., A.T.; Project Administration: B.M.D., C.K., R.G.K., K.S.V., A.T., B.S.C.; Funding Acquisition: J.N.T., B.M.D., R.G.K., A.T., B.S.C. All authors have read and agreed to the published version of the manuscript.

Funding: The trial was funded by Patient-Centered Outcomes Research Institute (PCORI) Contract Number CER-1402-10800. PCORI scientific staff played no role in study design and conduct. The statements presented in this publication are solely the responsibility of the author(s) and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute® (PCORI®), its Board of Governors or Methodology Committee. Additional research support was provided by pilot grants and an administrative supplement awarded to # UL1 TR001866 from the National Center for Advancing Translational Sciences (NCATS, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program and research infrastructure was supported in part by “Building a Network of Safety Network PBRNs” Grant # 1 P30-HS-021667 – Center of Excellence (P30) for Practice-based Research and Learning, Agency for Healthcare Research and Quality (AHRQ).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Boards at both the Clinical Directors Network (CDN) and The Rockefeller University. ClinicalTrials.gov Identifier: NCT02566928.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data will be made available on a case-by-case basis. Please contact the Corresponding Author for additional information.

Acknowledgments: The authors wish to thank the Clinical Directors Network, Inc. (CDN) Research Team (TJ Lin; Dena Moftah; Anthony Rhabb, Branny F. Tavarez, Cynthia Mofunanya, Jasbir Singh, Jessica Ramachandran, Leidy Johana González, Musarrat Rahman, Raul Silvero, Sisle Heyliger, Tameir Holder, Ummah Siddiqui, Viktorya Snkhchyan, Lois Lynn, Melissa Samanoglu), the The Rockefeller University Research Team (Barry S. Coller, Rhonda G. Kost, Joel Corrêa da Rosa, Roger Vaughan, Andrea Leinberger-Jabar, Cameron Coffran, Helen Marie Curry, Kimberly S Vasquez, Maia Neville Williams, Marilyn Chung, Teresa H. Evering, Mina Pastagia, Teresa L. Solomon, Alexander Tomasz, Herminia de Lancastre, Maria Pardos de la Gándara), the Federally Qualified Health Centers (FQHCs): Community Health Network (Satoko Kanahara, Tyler Evans), Family Health Centers at NYU Langone (William Pagano, Barry Kohn, Isaac Dapkins; Paula Clemons; Viral Patel, Jason Hyde, Maria Ferrer, Keenan Millan); Open Door Family Health Center (Daren Wu, Asaf Cohen), Urban Health Plan (Claude Parola, Tracie Urban, Franco A. Barsanti; Ali Saleh, Scott Salvato, Jennifer Concepcion), Hospital Emergency Departments (EDs): NYC Health + Hospitals/Coney Island Hospital ED (Regina Hammock; Rosalee Nguyen; Candace Gopaul; Ronette Davis), NYC Health + Hospitals/Metropolitan Hospital ED (Getaw Worku Hassan; Van Johnson), Patient and Community Stakeholders (Rosa Perez/Cordette Pharmacy and Dennis Mitchell/Denny Moe Barber Shop), the Data and Safety Monitoring Board (DSMB: Katherine Freeman, DSMB Chair/Extrapolate Statistics LLC and Florida Atlantic University; Marilyn Gaston/Assistant Surgeon General and HRSA Associate Administrator for Primary Health Care (ret.), Maria Ferrer/Patient Representative); Scientific Consultants/Advisors (Susan Huang, Christopher R. Frei, Eric Lofgren, Weill-Cornell Medicine (Christopher Mason, Ebrahim Afshinoko, Chou Chou), City University of New York (Shirshendu Chatterjee), New York City Department of Health and Mental Hygiene Public Health/Preventive Medicine Residency (Sarah Johnson), Bio-Reference Labs (Barbara Milioti, E Denise Digirolomo, Edward Clayton), MyOwnMed (Vicki Seyfert-Margolies, Dana Wershiner, Trang Gisler), Consulting Associates, Inc. (Suzanne Lechner).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
References

1. Farr, A.M.; Aden, B.; Weiss, D.; Nash, D.; Marx, M.A. Trends in hospitalization for community-associated methicillin-resistant Staphylococcus aureus in New York City, 1997–2006: Data from New York State’s Statewide Planning and Research Cooperative System. Infect. Control Hosp. Epidemiol. 2012, 33, 725–731. [CrossRef] [PubMed]

2. Moran, G.J.; Krishnasadan, A.; Gorwitz, R.J.; Fosheim, G.E.; McDougal, L.K.; Carey, R.B.; Talan, D.A. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 2006, 355, 666–674. [CrossRef] [PubMed]

3. Centers for Disease Control and Prevention. Methicillin-Resistant Staphylococcus aureus (MRSA) Infection in Healthcare Settings; 2012. Available online: http://www.cdc.gov/HA/organisms/mrsa-infection.html (accessed on 2 February 2019).

4. Klevens, R.M.; Morrison, M.A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L.H.; Lynfield, R.; Dumyati, G.; Townes, J.M.; et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298, 1763–1771. [CrossRef]

5. Huang, S.S.; Septimus, E.; Kleinman, K.; Moody, J.; Hickok, J.; Avery, T.R.; Lankiewicz, J.; Gombosev, A.; Terpstra, L.; Hartford, F.; et al. Targeted versus universal decolonization to prevent ICU infection. N. Engl. J. Med. 2013, 368, 2255–2265. [CrossRef]

6. Cluzet, V.C.; Gerber, J.S.; Metlay, J.P.; Nachamkin, I.; Zaoutis, T.E.; Davis, M.F.; Julian, K.G.; Linkin, D.R.; Coffin, S.E.; Margolis, D.J.; et al. The effect of total household decolonization on clearance of colonization with methicillin-resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 2016, 37, 1226–1233. [CrossRef]

7. Ellis, M.W.; Schlett, C.D.; Millar, E.V.; Wilkins, K.J.; Crawford, K.B.; Morrison-Rodriguez, S.M.; Pacha, L.A.; Gorwitz, R.J.; Lanier, J.B.; Trillo, D.R. Hygiene strategies to prevent methicillin-resistant Staphylococcus aureus skin and soft tissue infections: A cluster-randomized controlled trial among high-risk military trainees. Clin. Infect. Dis. 2014, 58, 1540–1548. [CrossRef] [PubMed]

8. Fritz, S.A.; Hogan, P.G.; Hayek, G.; Eisenstein, K.A.; Rodriguez, M.; Epplin, E.K.; Garbutt, J.; Fraser, V.J. Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: A randomized trial. Clin. Infect. Dis. 2012, 54, 743–751. [CrossRef] [PubMed]

9. Hogan, P.G.; Rodriguez, M.; Spennier, A.M.; Brenniseim, J.M.; Boyle, M.G.; Sullivan, M.L.; Fritz, S.A. Impact of Systemic Antibiotics on Staphylococcus aureus Colonization and Recurrent Skin Infection. Clin. Infect. Dis. 2018, 66, 191–197. [CrossRef]

10. Papastefan, S.T.; Buonpane, C.; Ares, G.; Benyamen, B.; Helenowski, I.; Hunter, C.J. Impact of decolonization protocols and recurrence in pediatric MRSA skin and soft-tissue infections. J. Surg. Res. 2019, 242, 70–77. [CrossRef]

11. Huang, S.S.; Singh, R.; McKinnell, J.A.; Park, S.; Gombosev, A.; Eells, S.J.; Gillen, D.L.; Kim, D.; Rashid, S.; Macias-Gil, R.; et al. Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers. N. Engl. J. Med. 2019, 380, 638–650. [CrossRef] [PubMed]

12. DeLeo, F.R.; Otto, M.; Kreiswirth, B.N.; Chambers, H.F. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010, 375, 1557–1568. [CrossRef]

13. May, L.; Klein, E.Y.; Martinez, E.M.; Mojica, N.; Miller, L.G. Incidence and factors associated with emergency department visits for recurrent skin and soft tissue infections in patients in California, 2005–2011. Epidemiol. Infect. 2017, 145, 746–754. [CrossRef]

14. Hogan, P.G.; Parrish, K.L.; Mork, R.L.; Carey, R.B.; Talan, D.A. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 2006, 355, 666–674. [CrossRef] [PubMed]

15. Miller, L.G.; Eells, S.J.; Taylor, A.R.; Ortiz, N.; Zychowski, D.; Kumar, N.; Cruz, D.; Boyle-Vavra, S.; Daum, R.S. Staphylococcus aureus colonization among household contacts of patients with skin infections: Risk factors, strain discordance, and complex ecology. Clin. Infect. Dis. 2012, 54, 1523–1535. [CrossRef]

16. Miller, L.G.; Tan, J.; Eells, S.J.; Benitez, E.; Radner, A.B. Prospective investigation of nasal mupirocin, hexachlorophene body wash, and systemic antibiotics for prevention of recurrent community-associated methicillin-resistant Staphylococcus aureus infections. Antimicrob. Agents Chemother. 2012, 56, 1084–1086. [CrossRef] [PubMed]

17. Knox, J.; Sullivan, S.B.; Urena, J.; Miller, M.; Vavagiakis, P.; Shi, Q.; Uhlemann, A.C.; Lowy, F.D. Association of Environmental Contamination in the Home With the Risk for Recurrent Community-Associated, Methicillin-Resistant Staphylococcus aureus Infection. JAMA Intern. Med. 2016, 176, 807–815. [CrossRef] [PubMed]

18. Fritz, S.A.; Camins, B.C.; Eisenstein, K.A.; Fritz, J.M.; Epplin, E.K.; Burnham, C.A.; Dukes, J.; Storch, G.A. Effectiveness of measures to eradicate Staphylococcus carriage in patients with community-associated skin and soft-tissue infections: A randomized trial. Infect. Control Hosp. Epidemiol. 2011, 32, 872–880. [CrossRef]

19. Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 2011, 52, e18–e55. [CrossRef] [PubMed]

20. Stevens, D.L.; Bisno, A.L.; Chambers, H.F.; Dellinger, E.P.; Goldstein, E.J.; Gorbach, S.L.; Hirschmann, J.V.; Kaplan, S.L.; Montoya, J.G.; Wade, J.C.; et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2014, 59, e10–e52. [CrossRef]
21. Piper Jenks, N.; Pardos de la Gandara, M.; D’Orazio, B.M.; Correa da Rosa, J.; Kost, R.G.; Khalida, C.; Vasquez, K.S.; Coffran, C.; Pastagia, M.; Evering, T.H.; et al. Differences in prevalence of community-associated MRSA and MSSA among US and non-US born populations in six New York community health centers. *Travel. Med. Infect. Dis.* 2016, 14, 551–560. [CrossRef]

22. Creech, C.B.; Al-Zubeidi, D.N.; Fritz, S.A. Prevention of Recurrent Staphylococcal Skin Infections. *Infect. Dis. Clin. North Am.* 2015, 29, 429–464. [CrossRef] [PubMed]

23. McNeil, J.C.; Fritz, S.A. Prevention strategies for recurrent community-associated *Staphylococcus aureus* skin and soft tissue infections. *Curr. Infect. Dis. Rep.* 2019, 21, 12. [CrossRef] [PubMed]

24. Daum, R.S.; Miller, L.G.; Immergluck, L.; Fritz, S.; Creech, C.B.; Young, D.; Kumar, N.; Downing, M.; Pettibone, S.; Hoagland, R.; et al. A placebo-controlled Trial of Antibiotics for Smaller Skin Abscesses. *N. Engl. J. Med.* 2017, 376, 2545–2555. [CrossRef] [PubMed]

25. Eells, S.J.; David, M.Z.; Taylor, A.; Ortiz, N.; Kumar, N.; Sieth, J.; Boyle-Vavra, S.; Daum, R.S.; Miller, L.G. Persistent environmental contamination with USA300 methicillin-resistant *Staphylococcus aureus* and other pathogenic strain types in households with S. aureus skin infections. *Infect. Control Hosp. Epidemiol.* 2014, 35, 1373–1382. [CrossRef]

26. Fritz, S.A.; Hogan, P.G.; Singh, L.N.; Thompson, R.M.; Wallace, M.A.; Whitney, K.; Al-Zubeidi, D.; Burnham, C.A.; Fraser, V.J. Contamination of environmental surfaces with *Staphylococcus aureus* in households with children infected with methicillin-resistant *S. aureus*. *JAMA Pediatrics* 2014, 168, 1030–1038. [CrossRef]

27. Knox, J.; Uhlemann, A.C.; Lowy, F.D. *Staphylococcus aureus* infections: Transmission within households and the community. *Trends Microbiol.* 2015, 23, 437–444. [CrossRef] [PubMed]

28. Knox, J.; Uhlemann, A.C.; Miller, M.; Hafer, C.; Vasquez, G.; Vavagiakis, P.; Shi, Q.; Lowy, F.D. Environmental contamination as a risk factor for intra-household *Staphylococcus aureus* transmission. *PLoS ONE* 2012, 7, e49900. [CrossRef]

29. Uhlemann, A.C.; Knox, J.; Miller, M.; Hafer, C.; Vasquez, G.; Ryan, M.; Vavagiakis, P.; Shi, Q.; Lowy, F.D. The environment as an unrecognized reservoir for community-associated methicillin resistant *Staphylococcus aureus* USA300: A case-control study. *PLoS ONE* 2011, 6, e22407. [CrossRef] [PubMed]

30. Hogan, P.G.; Mork, R.L.; Thompson, R.M.; Muenks, C.E.; Boyle, M.G.; Sullivan, M.L.; Morelli, J.J.; Williams, C.V.; Sanchez, N.; Hunstad, D.A.; et al. Environmental methicillin-resistant, persistent colonization, and subsequent skin and soft tissue infection. *JAMA Pediatrics* 2020, 174, 11. [CrossRef]

31. Baud, O.; Giron, S.; Aumeran, C.; Moully, D.; Bardon, G.; Besson, M.; Delmas, J.; Coignard, B.; Tristan, A.; Vandenesch, F.; et al. First outbreak of community-acquired MRSA USA300 in France: Failure to suppress prolonged MRSA carriage despite decontamination procedures. *Eur. J. Clin. Microbiol. Infect. Dis.* 2014, 33, 1757–1762. [CrossRef] [PubMed]

32. Tidwell, J.; Kirk, L.; Luttrel, T.; Pike, C.A. CA-MRSA Decolonization Strategies: Do They Reduce Recurrence Rate? *J. Wound Ostomy Cont. Nurs.* 2016, 43, 577–582. [CrossRef] [PubMed]

33. Finnell, S.M.; Rosenman, M.B.; Christenson, J.C.; Downs, S.M. Decolonization of children after incision and drainage for MRSA abscess: A retrospective cohort study. *Clin. Pediatrics* 2015, 54, 445–450. [CrossRef]

34. Ellis, M.W.; Griffith, M.E.; Dooley, D.P.; McLean, J.C.; Jorgensen, J.H.; Patterson, J.E.; Davis, K.A.; Hawley, J.S.; Regules, J.A.; Rivard, R.G.; et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant *Staphylococcus aureus* strains in soldiers: A cluster randomized controlled trial. *Antimicrob. Agents Chemother.* 2007, 51, 3591–3598. [CrossRef] [PubMed]

35. Goldberg, G.R.; Quinn, B.; Bergstrom, K.; Stockdale, D.; Woods, S.; Nsungu, M.; Brooke, B.; Levett, P.N.; Horsman, G.; McDonald, R.; et al. Community-based educational intervention to limit the dissemination of community-associated methicillin-resistant *Staphylococcus aureus* in Northern Saskatchewan, Canada. *BMJ Public Health* 2012, 12, 15. [CrossRef] [PubMed]

36. Tacoma-Pierce County Health Department. *Living with MRSA; Tacoma-Pierce County Health Department: Tacoma-Pierce, WA, USA, 2006.*

37. Petti, S.; De Giusti, M.; Moroni, C.; Polimeni, A. Long-term survival curve of methicillin-resistant *Staphylococcus aureus* on clinical contact surfaces in natural-like conditions. *Am. J. Infect. Control* 2012, 40, 1001–1012. [CrossRef]

38. Sehulster, L.M.C.R.; Arduino, M.J.; Carpenter, J.; Donlan, R.; Ashford, D.; Besser, R.; Fields, B.; McNeil, J.M.; Whitney, C.; Wong, S.; et al. Guidelines for Environmental Infection Control in Health-Care Facilities. Recommendations from CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC); American Society for Healthcare Engineering/American Hospital Association, 2004.

39. Hanitsch, L.G.; Krüger, R.; Hoppe, P.A.; Humme, D.; Pokrywka, A.; Niebank, M.; Stegemann, M.; Kola, A.; Leistner, R. Outpatient decolonization after recurrent skin infection with Panton-Valentine leukocidin (PVL)-producing S. aureus—The importance of treatment repetition. *PLoS ONE* 2020, 15, e0231772. [CrossRef]

40. Balachandra, S.; Pardos de la Gandara, M.; Salvato, S.; Urban, T.; Parola, C.; Khalida, C.; Kost, R.G.; Evering, T.H.; Pastagia, M.; D’Orazio, B.M.; et al. Recurrent furunculosis caused by a community-acquired *Staphylococcus aureus* strain belonging to the USA300 clone. *Microb. Drug Resist.* 2015, 21, 237–243. [CrossRef]

41. Pardos de la Gandara, M.; Raygoza Garay, J.A.; Mwangi, M.; Tobin, J.N.; Tsang, A.; Khalida, C.; D’Orazio, B.; Kost, R.G.; Leinberger-Jabari, A.; Coffran, C.; et al. Molecular types of methicillin-resistant *Staphylococcus aureus* strains causing skin and soft tissue infections and nasal colonization, identified in community health centers in New York City. *J. Clin. Microbiol.* 2015, 53, 2648–2658. [CrossRef]
42. Leinberger-Jabari, A.; Kost, R.G.; D’Orazio, B.; Burgess, R.; Khalida, C.; Tsang, A.; Mitchell, D.; Tomasz, A.; de Lencastre, H.; Pardos de la Gandara, M.; et al. From the bench to the barbershop: Community engagement to raise awareness about community-acquired methicillin-resistant \textit{Staphylococcus aureus} and hepatitis c virus infection. Prog. Community Health Partnersh. \textbf{2016}, \textit{10}, 413–423. [CrossRef]

43. Clinical and Laboratory Standards Institute (CLSI). \textit{Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement}. CLSI Document M100-S23; Clinical and Laboratory Standards Institute (CLSI): Wayne, PA, USA, 2013.

44. Agency for Healthcare Research and Quality. \textit{Warm Handoff: Intervention}; U.S. Department of Health and Human Services: Rockville, MD, USA, 2017. Available online: https://www.ahrq.gov/professionals/quality-patient-safety/patient-family-engagement/pfeprimarycare/interventions/warmhandoff.html/ (accessed on 15 January 2017).

45. Cluzet, V.C.; Gerber, J.S.; Nachamkin, I.; Metlay, J.P.; Zaoutis, T.E.; Davis, M.F.; Julian, K.G.; Royer, D.; Linkin, D.R.; Coffin, S.E.; et al. Duration of colonization and determinants of earlier clearance of colonization with methicillin-resistant \textit{Staphylococcus aureus}. Clin. Infect. Dis. \textbf{2015}, \textit{60}, 1489–1496. [CrossRef]

46. Huang, S.S.; Septimus, E.; Kleinman, K.; Moody, J.; Hickok, J.; Heim, L.; Gombosev, A.; Avery, T.R.; Haffenreffer, K.; Shimelman, L.; et al. Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): A cluster-randomised trial. \textit{Lancet} \textbf{2019}, \textit{393}, 1205–1215. [CrossRef]

47. Lopez, G.U.; Kitajima, M.; Havas, A.; Gerba, C.P.; Reynolds, K.A. Evaluation of a disinfectant wipe intervention on fomite-to-finger microbial transfer. \textit{Appl. Environ. Microbiol.} \textbf{2014}, \textit{80}, 3113–3118. [CrossRef] [PubMed]

48. Lowe, C.F.; Lloyd-Smith, E.; Sidhu, B.; Ritchie, G.; Sharma, A.; Jang, W.; Wong, A.; Bilawka, J.; Richards, D.; Kind, T.; et al. Reduction in hospital-associated methicillin-resistant \textit{Staphylococcus aureus} and vancomycin-resistant \textit{Enterococcus} with daily chlorhexidine gluconate bathing for medical inpatients. Am. J. Infect. Control \textbf{2017}, \textit{45}, 255–259. [CrossRef] [PubMed]

49. Mehta, S.; Hadley, S.; Hutzel, L.; Slover, J.; Phillips, M.; Bosco, J.A. 3rd. Impact of preoperative MRSA screening and decolonization on hospital-acquired MRSA burden. \textit{Clin. Orthop. Relat. Res.} \textbf{2013}, \textit{471}, 2367–2371. [CrossRef] [PubMed]

50. Ridenour, G.; Lampen, R.; Federspiel, J.; Kritchevsky, S.; Wong, E.; Climo, M. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant \textit{Staphylococcus aureus} colonization and infection among intensive care unit patients. \textit{Infect. Control Hosp. Epidemiol.} \textbf{2007}, \textit{28}, 1155–1161. [CrossRef] [PubMed]